Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 21 04:00PM ET
24.10
Dollar change
-1.53
Percentage change
-5.97
%
Index- P/E- EPS (ttm)-71.38 Insider Own11.40% Shs Outstand50.78M Perf Week-25.53%
Market Cap1.22B Forward P/E- EPS next Y-3.89 Insider Trans0.00% Shs Float44.99M Perf Month-33.22%
Income-364.23M PEG- EPS next Q-0.95 Inst Own64.69% Short Float10.17% Perf Quarter-39.54%
Sales0.69M P/S1773.62 EPS this Y92.00% Inst Trans-10.48% Short Ratio10.73 Perf Half Y46.95%
Book/sh-0.89 P/B- EPS next Y1.00% ROA-134.88% Short Interest4.58M Perf Year806.02%
Cash/sh9.54 P/C2.53 EPS next 5Y- ROE-391.81% 52W Range2.66 - 47.97 Perf YTD11.99%
Dividend Est.- P/FCF- EPS past 5Y1.60% ROI-89.78% 52W High-49.76% Beta2.94
Dividend TTM- Quick Ratio11.38 Sales past 5Y-49.91% Gross Margin39.53% 52W Low806.02% ATR (14)3.01
Dividend Ex-Date- Current Ratio11.38 EPS Y/Y TTM-201.00% Oper. Margin-22897.09% RSI (14)29.95 Volatility13.45% 9.76%
Employees30 Debt/Eq1.66 Sales Y/Y TTM-40.94% Profit Margin-52939.68% Recom1.14 Target Price47.33
Option/ShortYes / Yes LT Debt/Eq1.66 EPS Q/Q75.42% Payout- Rel Volume3.78 Prev Close25.63
Sales Surprise- EPS Surprise-14.41% Sales Q/Q-100.00% EarningsMay 09 AMC Avg Volume426.47K Price24.10
SMA20-27.17% SMA50-30.35% SMA200-0.94% Trades Volume1,612,480 Change-5.97%
Date Action Analyst Rating Change Price Target Change
May-02-24Initiated Robert W. Baird Outperform $50
Mar-01-24Upgrade Wells Fargo Equal Weight → Overweight $12 → $35
Dec-20-23Initiated BTIG Research Buy $32
Dec-11-23Initiated Jefferies Buy $31
Dec-11-23Initiated Guggenheim Buy $44
May-04-20Initiated Piper Sandler Overweight $12
Mar-21-19Initiated JP Morgan Overweight $14
Sep-04-18Downgrade Wells Fargo Outperform → Market Perform
Apr-24-18Initiated Evercore ISI Outperform $37
Mar-14-18Reiterated Needham Buy $8 → $12
Jun-18-24 07:30AM
Jun-03-24 05:23PM
May-29-24 08:30AM
May-15-24 07:30AM
May-09-24 10:54PM
04:02PM Loading…
04:02PM
May-03-24 05:00PM
Apr-01-24 05:00PM
Mar-18-24 08:00AM
Mar-04-24 08:50AM
Mar-01-24 05:25PM
Feb-29-24 04:05PM
Feb-26-24 07:30AM
Feb-08-24 07:30AM
Feb-06-24 09:55AM
07:30AM Loading…
Feb-05-24 07:30AM
Feb-02-24 05:30PM
Dec-22-23 05:00PM
Dec-08-23 07:19AM
Dec-07-23 06:20PM
Nov-28-23 08:00AM
Nov-27-23 08:30AM
Nov-22-23 05:00PM
Nov-09-23 06:26PM
04:05PM
Nov-03-23 05:00PM
Oct-30-23 08:00PM
Oct-02-23 06:02PM
Sep-14-23 05:03PM
Sep-07-23 08:40AM
07:00AM Loading…
Sep-05-23 07:00AM
Aug-11-23 07:07AM
07:00AM
Jul-27-23 07:00AM
Jun-23-23 04:30PM
10:31AM
Jun-22-23 10:59AM
08:17AM
May-13-23 08:03AM
May-11-23 08:15AM
07:10AM
07:01AM
Apr-13-23 09:44AM
Apr-12-23 07:00AM
Mar-17-23 05:30PM
Mar-02-23 10:15AM
07:01AM
Feb-12-23 07:40AM
Jan-06-23 07:01AM
Jan-02-23 07:29AM
Dec-14-22 12:00PM
Dec-02-22 04:05PM
Nov-30-22 10:38AM
07:01AM
Nov-15-22 04:25PM
Nov-03-22 08:35AM
07:01AM
Oct-21-22 12:27PM
12:06PM
Oct-19-22 04:05PM
Oct-17-22 11:57AM
Oct-04-22 11:05AM
07:01AM
Aug-29-22 04:05PM
Aug-27-22 09:18AM
Aug-25-22 11:52AM
Aug-24-22 12:40PM
08:01AM
Aug-22-22 12:28PM
Aug-20-22 10:49AM
Aug-19-22 06:26AM
Aug-18-22 04:05PM
Aug-04-22 08:35AM
07:01AM
Jul-24-22 10:41AM
Jul-08-22 11:14AM
Jul-07-22 11:22AM
Jul-04-22 11:49AM
Jun-29-22 12:34PM
Jun-28-22 11:52AM
10:23AM
Jun-13-22 12:01PM
Jun-09-22 09:56AM
Jun-03-22 10:49AM
Jun-02-22 03:26PM
03:20PM
12:09PM
11:24AM
08:59AM
Jun-01-22 02:25PM
02:22PM
May-31-22 11:26AM
May-26-22 11:18AM
May-25-22 12:07PM
May-23-22 11:46AM
11:33AM
May-20-22 09:50AM
May-18-22 11:47AM
11:03AM
May-17-22 11:31AM
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fairmount Funds Management LLCDirectorApr 25 '24Option Exercise0.003,639,68004,018,101Apr 25 04:55 PM